Orbital rhabdomyosarcomas: A review  by Jurdy, Lama et al.
Saudi Journal of Ophthalmology (2013) 27, 167–175Ocular Oncology UpdateOrbital rhabdomyosarcomas: A reviewPeer review under responsibility
of Saudi Ophthalmological Society,
King Saud University Production and hosting by Elsevier
Access this article onlin
www.saudiophthaljourn
www.sciencedirect.com
Available online 24 June 2013
a Orbital Centre, Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Ams
The Netherlands
b Department of Paediatric Oncology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Neth
c Department of Radiotherapy, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlan
d Department of Plastic and Reconstructive Surgery, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Ams
The Netherlands
⇑ Corresponding author. Tel.: +31 614067290.
e-mail address: p.saeed@amc.uva.nl (P. Saeed).Lama Jurdy, MD a; Johanus H.M. Merks, MD, PhD b; Bradly R. Pieters, MD, PhD c; Maarten P. Mourits, MD, PhD a;
Roel J.H.M. Kloos, MD a; Simone D. Strackee, MD, PhD d; Peerooz Saeed, MD, PhD a,⇑AbstractRhabdomyosarcoma (RMS) is a highly malignant tumor and is one of the few life-threatening diseases that present first to the oph-
thalmologist. It is the most common soft-tissue sarcoma of the head and neck in childhood with 10% of all cases occurring in the
orbit. RMS has been reported from birth to the seventh decade, with the majority of cases presenting in early childhood. Survival
has changed drastically over the years, from 30% in the 1960’s to 90% presently, with the advent of new diagnostic and therapeutic
modalities. The purpose of this review is to provide a general overview of primary orbital RMS derived from a literature search of
material published over the last 10 years, as well as to present two representative cases of patients that have been managed at our
institute.
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Rhabdomyosarcoma (RMS) is a highly malignant tumor in
which the tissue of origin is pluripotent mesenchyme.1
It is the most common soft-tissue sarcoma of the head and
neck in childhood and comprises 4% of all pediatric malig-
nancies, with 10% of all cases occurring in the orbit.1,2
Most of these tumors occur in the first decade of life,3 how-
ever RMS has been reported from birth to the eighth
decade.1,4,5
The incidence of malignant orbital tumors in general has
been increasing.6 Turner et al. in a study of population based
incidence and survival in head and neck RMS reported an an-
nual percentage increase of 1.16% and a statistically un-
changed 5-year survival over the past 30 years despiteadvances in treatment modalities; although other studies
have reported improved survival.3,7 Relative survival (RS)
was more dependent on the extent of disease rather than
primary site, and it was noted that most orbital RMS tumors
(60.6%) presented with localized disease and consequently
had a 5-year survival of about 84.3% which is more favorable
when compared with other sites in the head and neck.3,8
Other factors positively influencing survival were younger
age (<10 years), female sex and embryonal histology (the
most common in the orbit).3,4,8–10
Ocular RMS comprises tumors that occur in the orbit, or
rarely in other ocular adnexal structures or within the eye.2
The purpose of this review is to provide a general overview
of primary orbital RMS derived from a literature search of
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aged at our institute.
Orbital RMS is one of the few life-threatening diseases
that present first to the ophthalmologist; therefore prompt
diagnosis and treatment is a life-saving issue.2 Hence,
knowledge of the clinical, histopathological, and radio-
graphic features as well as the more recent advances in the
management of this entity is essential.
Clinical features
Patients with orbital RMS usually present with proptosis
developing rapidly over weeks (80–100%), or globe displace-
ment (80%) which is usually downward and outward because
two-thirds of these tumors are supero-nasal.1,2,4
Metastatic spread of orbital RMS is uncommon, however if
left untreated RMS has a propensity to metastasize to the
lung, bone and bone marrow mainly via hematogenous
spread (because orbital lymphatics are scarce).2 Locally, orbi-
tal RMS can invade the orbital bones and can extend intracra-
nially.2 Metastatic orbital RMS has an unfavorable prognosis
when compared to localized disease; however in a joint Euro-
pean-North American pooled analysis orbital site proved to
be favorable.2,11,12
Diagnosis
A detailed history is essential in any child suspected to
have orbital RMS (i.e. under 2 years of age and presenting
with an orbital mass).2 The ophthalmologist should specifi-
cally ask about pain, visual loss, and signs of sinusitis, and
should also keep in mind possible misleading presentations
such as rapidly progressing alterations of the lid, conjunctiva
or caruncle.2,13
The history will help exclude other differential diagnoses
such as orbital cellulitis, lymphangioma, idiopathic orbital
inflammation, dermoid cyst, hemangioma, Langerhans cell
histiocytosis (eosinophilic granuloma), sarcomas, metastatic
neuroblastoma, and lymphoma.2 Imaging also plays an
important role in the differentiation of these conditions.
Biopsy should be performed if RMS is suspected based on
clinical and radiological findings.2
Imaging
Orbital RMS is usually extraconal (37–87%) or both intra-
and extraconal (13–47%), and more commonly superonasal
in location especially for embryonal RMS (inferior location is
more common for alveolar).4,9,14–16 The mass is usually close
to extraocular muscles, but there is no enlargement of the
muscle belly.9 In early stages the tumor is well circumscribed,
but in later stages, where there is pseudocapsular invasion,
the borders are irregular.2 There may be some bone defor-
mity, but frank bone destruction with bone involvement is
rare, and the diagnosis in this case will change from orbital
to parameningeal RMS.15 The tumor may show hemorrhages
and cyst formation.2
Ultrasound (US)
US findings are neither specific for orbital RMS nor sensi-
tive for detecting parameningeal spread, and US penetrationinto deeper tissues is limited; hence reports on US findings in
orbital tumors are limited.9,15,17 It mainly appears as a well-
circumscribed, heterogenous, irregular mass with low to
medium echogenicity on US and a variable intratumoral vas-
cular flow pattern on Doppler US.9,17 A ‘‘pseudocystic’’
appearance has been reported as characteristic, and that is
thought to be due to spindle cells in embryonal RMS which
have abundant cytoplasm and are separated loosely by
edematous fluid.18
Computed tomography (CT) and magnetic resonance
imaging (MRI)
CT and MRI are important for the preoperative evaluation,
staging, and follow-up of orbital RMS.6 CT is especially
important for the detection of bone involvement, and MR is
important for better spatial resolution, soft-tissue contrast,
and detection of intracranial spread.9,14 Both are also used
for post-treatment follow up: CT to show change in bone
involvement, and MR to show residual or recurrent disease.6
Hence, CT and MR are complementary.4,14,15 However, when
using CT one must be aware that exposure to ionizing radia-
tion may theoretically induce a second potentially fatal can-
cer in children who have already manifested a tendency to
harbor cancer; therefore, especially for follow up purposes
MRI is the preferred imaging modality.19
CT
Orbital RMS appears as a well-circumscribed, homoge-
nous, soft tissue mass that is isodense as compared to muscles
without bone destruction in earlier stages, but with invasion of
surrounding structures and calcification in more advanced
cases where there is destruction of the adjacent
bone.2,4,9,14,16,20 A heterogeneous appearance is possible in
the event of focal hemorrhage or necrosis, and there is mod-
erate to marked general enhancement with intravenous con-
trast.1,2,4,9,16 A common finding is eyelid thickening,
regardless of lid involvement, and a less common finding is
a cavitated mass with ring-like enhancement.9,14
MRI
On MRI, the tumor appears isointense with respect to
extraocular muscles and hypointense with respect to orbital
fat on T1-weighted images, and hyperintense (with respect
to both orbital fat and extraocular muscles) on T2-weighted
images.4,16,20 Increased signal on T1 and T2 is seen in focal
areas of chronic hemorrhage.1 The globe may be distorted
or displaced but rarely invaded.9 Visualization is best with
gadolinium, (moderate to marked enhancement), and fat
suppression for better delineation.2 Pre- and postcontrast
comparison is useful to best detect intracranial and adjacent
paranasal sinus invasion.14
Diffusion-weighted imaging (DWI) is an MR imaging tech-
nique that gives information about normality of proton and
water diffusion through tissue characterized by DWI and
ADC (Apparent Diffusion Coefficient) values, respectively.21
Because of high cellular density, malignant tumors usually
have restricted diffusion. Lope et al. studied the usefulness
of DWI in identifying characteristics of orbital tumors in order
to aid radiographic diagnosis.21 They found that RMS was
Figure 2. Alveolar orbital RMS. The cells are large, with abundant
eosinophilic cytoplasm and round to polygonal in shape with vesicular
nuclei which are a diagnostic feature of alveolar type as opposed to
embryonal.
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helpful in differentiating it from hemangioma, (which has in-
creased DWI/ADC) since the two exhibit a similar appearance
on T1 and T2.21
Nuclear imaging
Bone scintigraphy is being used in the work-up particularly
for the detection of osteoblastic metastases.14
Some studies have demonstrated that PET-CT is better at
the detecting bone and lymph node metastasis than CT and
US; however whole body MR is being advocated (sensitivity
97.5%, specificity 99.4%) as superior to PET-CT (sensitivity
90%, specificity 100%).14,15,22 It is still unclear whether PET-
CT or whole body MR should be used routinely because of
lack of clinical trials aimed at RMS, however, they can be con-
templated in cases with increased metastatic risk.14
Biopsy
RMS is the most common biopsied malignant orbital tu-
mor in a child, and it is important in terms of establishing
diagnosis and determining prognosis.2,23 The biopsy can be
incisional or excisional based on clinical and imaging findings,
however fine needle aspiration is less useful because the lim-
ited amount of tissue obtained is usually insufficient for path-
ological diagnosis.
We advise incisional biopsy, as opposed to excisional, in
order to avoid dissemination of tumor cells into the adjacent
healthy tissue.
Pathology
Previously, RMS was believed to arise from extraocular
muscles, but now it is thought that it originates from pluripo-
tent mesenchymal cells that have the ability to differentiate
into skeletal muscle.2,9,20 Some cases may be related to prior
radiation.2
RMS is divided into three histological subgroups: pleo-
morphic, embryonal, and alveolar; with the majority of orbital
RMS being of the embryonal type, and the pleomorphic sub-
type occurring almost exclusively in adults (median age: sixth
decade).2Figure 1. Embryonal orbital RMS. Elongated to round spindle cells with
features of skeletal muscle in different stages of embryogenesis with a
highly eosiniphilic cytoplasm and hyperchromatic nuclei.The embyonal type (Fig. 1) comprises 50–70% of orbital
RMS. Frequently seen cells are bipolar cells with tapered
cytoplasmic processes, and less commonly seen cells are
‘‘tadpole-like’’ with long cytoplasmic extensions.9 The cells
are usually arranged in a pattern of interlacing fascicle.9
Cross-striations (which are bundles of actin and myosin fila-
ments) in the cytoplasm may be visible with Masson tri-
chrome or phosphotungstic acid–hematoxylin stains.2,9,20
The alveolar type (Fig. 2) (20–30% of orbital RMS) is char-
acterized by ill-defined aggregates of poorly differentiated
malignant cells that are loosely arranged and separated into
irregular ovoid spaces by thin fibrovascular septa in an alveo-
lar pattern which is absent in the ‘‘solid’’ form.2,9,20,24 This
type has a poor prognosis, and any focus of alveolar mor-
phology is sufficient to classify the tumor as alveolar RMS.24
The botryoid seems to be a variant of the embryonal type
that assumes a papillary configuration.2
Distinction of the different types of RMS is important and
can be aided by immunohistochemical staining and cytoge-
netic studies.24Immunohistochemistry
Immunohistochemical studies constitute the main ap-
proach to diagnosis. The markers typically found in RMS in-
clude antibodies against desmin (90%), muscle-specific
actin, myoD1 (71–91%) and myoglobin.2,23,25–28 Myogenin
(90%) is expressed more in the alveolar than in the embryonal
type.24–26,28,29 Vimentin and desmin are usually positive but
less specific since they can be positive in other tumors with
skeletal muscle differentiation.2,25,30
Myogenin and MyoD1 are myogenic transcriptional regu-
lators that are expressed early in skeletal muscle differentia-
tion (earlier than desmin, actin, myoglobin and myosin).25Electron microscopy
Not usually used for diagnosis of RMS, but may be helpful
if histopathologic diagnosis is uncertain by demonstrating
parallel arrays of thick myosin filaments.2
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RMS has been noted to occur more commonly in certain
familial syndromes like Li-Fraumeni familial cancer syndrome
(associated with p53 mutation), neurofibromatosis, Noonan,
Beckwith–Wiedemann and Costello syndromes which sug-
gest a possible genetic contribution to RMS.2,24,31–33
The most common cytogenetic finding in alveolar RMS is a
t(2;13)(q35–37;q14) translocation resulting in a transcript
composed of 50 PAX3 sequences fused to 30 FKHR se-
quences, and another translocation found in a subset of alve-
olar RMS is t(1;13)(p36;q14).24,26 One of these two fusion
genes is usually found in the majority of alveolar RMS.24,26
It is of note that the detection of PAX3-FKHR fusion protein
indicates an unfavorable variant of alveolar RMS, whereas
the PAX7-FKHR fusion protein indicates a relatively favorable
variant.10,34
p53 in RMS varies in a different series ranging from 5% to
44% of cases; CDK4 (cyclin-dependent kinase 4) is also a cell
cycle control gene reported to be positive in about 80% of
alveolar RMS.25,26 C-erbB2 expression is reported to be posi-
tive in 60% of cases of RMS.25 In a study by Andrade et al.,
the investigators found p53 to be positive in 13.8%, CDK4
in 34.5%, C-erbB2 in 70.4% and FAS in 31% of cases.25
Chan et al. reported hypermethylation of three tumor sup-
pressor genes (HIN-1, RB1, and CDX-1) in a patient with alve-
olar RMS, in addition to HIC-1 (present in 100% of studied
alveolar RMS cases).35 This is important especially in light of
the absence of MyoD1 methylation in this patient, knowing
that it is present in 91% of embryonal RMS.35 This can thus
play a role in differentiating embryonal and alveolar RMS;
however the sample size was too small to make definitive
conclusions and further studies are warranted.35
Staibano et al. studied DNA ploidy and immunohisto-
chemical expression of p53 (tumor suppressor gene), bcl-2
(protooncogene), MDR-1 (multidrug resistance protein) and
MIB1 (Ki67; cell proliferation associated protein) in the prog-
nostic evaluation of orbital RMS.7,26 They divided their find-
ings into two groups:
- Good prognosis i.e. relapse free.
- Poor prognosis i.e. relapsing RMS requiring more aggres-
sive therapeutic protocols.
Their results showed that the cases of tetraploid and/or
multiploid RMS overexpressing p53 and MDR-1 were charac-
terized by a worse prognosis; whereas tumors with a good
prognosis showed hyperexpression of MIB1 and absence of
mutated p53 expression.7,36 No difference was found with re-
spect to bcl-2 expression.7
It is worth noting that the point mutations of p53 as re-
lated to recurrence/progression/worse prognosis is still con-
troversial in the literature.25,31
These findings, and further studies, can prove useful for
subtyping RMS and tailoring treatment protocols.7
Management
Guidelines regarding management of RMS since the
early seventies have been intoduced mostly by the North
American Intergroup Rhabdomyosarcoma Study Group
(IRSG) and European cooperative groups: International
Society of Pediatric Oncology-Malignant Mesenchymal Tu-mor Committee (SIOP-MMT), Cooperative Weichteilsarkom
Study Group (CWS) and Italian Cooperative Group (ICG).2
Prior to that, overall survival (OS) was about 25–30% (with
the historically recommended treatment being exenteration
prior to the late 1960’s), and with the introduction of sur-
gery combined with adjuvant chemotherapy as well as
radiotherapy in cooperative group trials OS improved to
around 90%.1,4,10,15,37–40
Although the IRSG is directed at RMS in general, some
investigators have retrieved data that pertains only to orbital
RMS.2,41 The IRSG conclusions represent the American
school of thought, whereas the findings SIOP-MMT, CWS
and ICG represent the European school of thought.2,42,40
The diagnosis of orbital RMS is made based on histo-
pathologic findings following excisional or incisional
biopsy.2 Some surgeons believe that an incisional biopsy
is sufficient (European protocol) since adequate margins
cannot be reached and orbital RMS has a good prognosis
following radiation and chemotherapy regardless of
amount of tissue excised.43 Others believe that complete
excision or maximal debulking decreases the tumor burden
and facilitates subsequent medical treatment.2 In a pooled
analysis of 306 patients with orbital RMS treated according
to international protocols (IRSG, SIOP-MMT, CWS, and
ICG) in the period 1978–1992, 222/306 (72%) of patients
underwent an initial inicisional biopsy only and had tumors
that were considered unresectable.40 A partial excision was
achieved by an initial surgery in 75/306 patients (25%), and
in only 9/306 patients (3%) an initial oncological radical
excision could be performed. Although the initial surgical
approach differed between cooperative groups, with the
percentage of patients starting therapy after biopsy only
varying from 82% (IRSG) to 46% (ICG), this had no impact
on prognosis.
Following biopsy, staging for orbital RMS is internationally
uniformly done according to the IRS post-surgical staging
system.22,44–46
Group I: localized disease, completely resected (excisional
biopsy).
Group II: microscopic disease remaining after biopsy.
Group III: gross residual disease remaining after biopsy.
Group IV: distant metastasis present at onset.
This classification is useful in terms of treatment, stratifica-
tion and prognosis prediction.2,44
Decision-making for management is based on histopatho-
logic confirmation as well as staging of orbital RMS, which is
done by reviewing imaging (MRI of primary tumor, chest-CT,
Tc bone scan), pathology, and further work-up for metastases
(bilateral bone marrow punctures and trephines).1
Current management includes surgery, irradiation and
chemotherapy depending on the stage.2,47–49
- Group I are treated with chemotherapy only: VA (vincris-
tine and actinomycin).
- Group II are treated with a combination of chemotherapy
(VA and cyclophosphamide; VAC) and radiotherapy
(36 Gy).
- Group III are treated with a combination of chemotherapy
(VAC) and radiotherapy (45 Gy).
- Group IV are treated with a combination of intensive che-
motherapy and radiotherapy.
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phosphamide based on the IRSGIII and IV.12,49 Details
regarding the different possible chemotherapeutic regimens
depending on the risk is beyond the scope of this article but
have been reported in the literature.49,50,47,51
The current European pediatric Soft tissue sarcoma Study
Group (EpSSG) protocol (EpSSG-RMS-2005) proposes the
following treatment strategy.42,52
Group I: chemotherapy consisting of VA.
Groups II and III: chemotherapy VA with Ifosfamide added
in the first four courses; when in complete remission after
three chemotherapy courses policy is to either leave out
radiotherapy but add more ifosfamide, or add radiother-
apy (36 Gy) and leave out further ifosfamide. Those not
in complete remission after induction chemotherapy get
radiotherapy (45 Gy) without further ifosfamide.
Group IV: intensified chemotherapy regimen (IVA and
doxorubicin) followed by one year of maintenance chemo-
therapy and radiotherapy to all involved sites (when
possible).
A pooled analysis on 306 orbital RMS patients according
to European and North American protocols showed 10 year
EFS to be significantly better for patients receiving RT as part
of their initial treatment compared to those who did not (82 v
53%), however confirmed no statistical difference in OS (87 v
86%), taking advantage of a favorable ‘salvage gap’ with res-
cue utilizing further treatment.40 SIOP group data from that
analysis showed that up to 40% of patients with an orbital
localization could be treated successfully without the use of
RT and without disadvantage to the survival of the whole
group. However, the total burden of therapy must be taken
into account as those who relapsed not only received RT as
part of their second therapy but also needed additional
chemotherapy.40
Breneman et al. reported no change in prognosis with re-
duced doses of radiotherapy with the addition of a moderate
cumulative dose of cyclophosphamide.31 No specific guide-
lines concerning radiotherapy were specified apart from the
use of brachytherapy whenever possible.31,53
Brachytherapy has been used for local treatment at our
center since 1991.15 The AMORE protocol is a novel tech-
nique established at our institute for the treatment of non-
resectable head and neck RMS.55 This protocol has since
been followed for orbital RMS with the only remark that
reconstruction is often not needed at the orbital site.54,53 It
consists of Ablative surgery, MOulage technique brachyther-
apy and surgical REconstruction; it targets residual tumor
mass.15,55 After diagnosis and staging, chemotherapy is gi-
ven according to the European protocol, after which imaging
is repeated to look for residual disease.15 The aim of this pro-
tocol is to maximize local treatment and to avoid external
beam radiotherapy (EBRT). Ablative surgery is performed
as conservatively as possible with an effort not to sacrifice
important tissue at the expense of possible microscopic rem-
nants- which will be amenable to the brachytherapy which is
initiated directly post surgery.15,55 Brachytherapy has advan-
tages over EBRT including a reduction in the treatment time
and a focused dose delivery to the tumor bed and rapid
fall-off of the dose beyond the treatment volume, this way
sparing surrounding tissues and reducing morbidity, allowingorgan preservation and bone growth, potentially improving
the functional and cosmetic outcome.55
Radiotherapy
Radiation is usually in the range of 3600–5040 cGy over 4–
5 weeks, and in the case of parameningeal extension the re-
gion of extension is irradiated + 2 cm.1,2,52
The main goal in novel management options is to maintain
excellent survival while reducing the late side effects of treat-
ment.58 All of this has prompted enthusiasm for no or re-
duced-dose radiotherapy in low-risk RMS2,14,41,48,49,31,56 and
for new technologies in radiation oncology including proton
beam radiotherapy, intensity modulated radiotherapy
(IMRT), 3-D conformational radiotherapy and implant brachy-
therapy all with the goal to minimize dose to normal
tissue.15,22,43,57,58
IMRT
Wolden et al. studied IMRT for head-and-neck RMS where
they used a smaller margin (1.5 cm as opposed to the stan-
dard 2 cm in IRSG protocols) made possible by using imaging
(CT, PET, MR) in radiotherapy planning.59 They concluded
that IMRT with image fusion achieved excellent local control
(in cases that did not have alveolar histology) with minimal
dose reaching adjacent tissue when dose-limiting structures
are adjacent to the tumor.10,36,59
Hein et al. focused on the possibility of organ-sparing (par-
ticularly lens-sparing) irradiation in children with orbital RMS
by using IMRT as opposed to 3D conformational photon
radiotherapy.60 They concluded that although IMRT resulted
in a reduced dose to the lens (in treating tumors in retrobul-
bar and lateral positions) and ipsilateral lacrimal gland, no
significant difference was noted for the ipsilateral retina
and optic nerve, and more importantly, it resulted in an ex-
panded volume of the brain receiving low dose radiation as
compared to 3D conformational radiotherapy.60
Fractionated proton radiotherapy
Yock et al. reported results on using fractionated proton
radiotherapy as superior over 3D conformational photon
radiotherapy for orbital RMS; they concluded that proton
therapy achieves excellent tumor coverage at the same time
as it reduces radiation to the adjacent normal tissue like the
brain, pituitary, hypothalamus, temporal lobes, and ipsilateral
and contralateral orbital structures.10,36,54,61 Proton irradia-
tion has excellent potential for conformal treatment to nor-
mal tissue that is better than 3D conformal radiation and
perhaps even IMRT- which although advanced in tumor
targeting as compared to 3D conformational photon irradia-
tion- does distribute low dose to normal tissue: a disadvan-
tage in a pediatric population with excellent survival that is
more prone to secondary malignancies and growth
retardation.60,61
Intensity-modulated brachytherapy (IMBT)
Perioperative IMBT has also been studied, and in cases of
refractory orbital RMS was found to improve local tumor con-
trol and quality of life.62
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Brachytherapy offers a high dose to the tumor bed with a
low dose to the surrounding tissues and can be considered in
cases where radiotherapy is necessary and brachytherapy
characteristics fit; and although there are no conclusive
clinical data available yet, the findings after IMRT might seem
to be less favorable than those of brachytherapy.54,53
Following SIOP guidelines, Blank et al. have recently re-
ported the use of brachytherapy instead of EBRT as part of
the treatment of orbital RMS.54 The side effects were found
to be very low and not clinically significant. They thus con-
cluded that surgery followed by brachytherapy can be con-
sidered when there is no residual intracranial extension of
the tumor after chemotherapy, macroscopic tumor removal
is feasible, and when EBRT is expected to be harmful to
eye structures.54Side effects of radiotherapy
Many complications can arise from treatment with EBRT,
including cataract (55%), dry eyes (36%), orbital hypoplasia
(24%), ptosis (9%), radiation retinopathy (90%), facial asym-
metry secondary to bone hypoplasia, keratoconjunctivitis,
lacrimal duct stenosis, dental defects, growth retardation
(in case of incidental irradiation of the pituitary) and second-
ary neoplasms such as osteogenic sarcoma, lymphoblastic
leukemia and melanoma.1,2,41,57,58,63
Although brachytherapy is not free of side effects, it is less
toxic than EBRT especially with respect to orbital hypopla-
sia.54,53,57 The side effects of brachytherapy can include cat-
aract, radiation retinopathy, dryness, ptosis; all of which are
relatively mild and/or amenable to treatment.54Evaluation of metastatic disease
Work-up for metastatic disease should include chest-CT,
Tc bone scan, and bone marrow punctures and trephines.
Staging combines TNM (tumor, nodes, metastasis), which in-
cludes clinical features, histological grade, and the clinical
grouping classification for RMS by the IRSG.14,25 A pooled
analysis of 788 metastatic patients treated according to
international cooperative group protocols (IRSG/COG,
SIOP-MMT, ICG) in the time period 1984–2000 revealed that
3-year event free survival (EFS) was significantly and
adversely influenced by age (61 or P10 years), location of
the primary tumor at an unfavorable site (defined as extrem-
ity and ‘‘other’’ sites, the latter predominantly meaning trunk,
excluding bladder and prostate), presence of three or more
sites of metastatic disease, and the presence of bone or bone
marrow involvement. EFS was 50% for patients with zero ad-
verse factors and was respectively 42%, 18%, 12%, and 5% in
patients with one, two, three, or four factors.12Figure 3. MR orbits and brain. Large intraorbital mass with local invasion
of the lamina papyracea and no intracranial extension.Recurrence
Recurrence of orbital RMS can occur in about 17% of cases
at a median time of 18 months, with 92% of these cases being
local and 8% at distant sites.14,64 There are no clear guide-
lines for treatment in cases of recurrence. Possible options in-
clude debulking in addition to chemotherapy, additionalEBRT, brachytherapy; and if all fails, exenteration is the
remaining option.2,37,47
Follow-up
Follow-up of patients post treatment for orbital RMS is
essential in order to look for late side-effects of radiotherapy,
recurrence and secondary tumors. Radiological follow up
with MRI is specified in cooperative group protocols and will
generally start at 3 month intervals, with decreasing fre-
quency until 5 years after treatment. Initially, ocular examina-
tion has to be done every 3–4 months, and after the first year
every 4–6 months for several years and then yearly; and
depending on the clinical findings periodic imaging can be
done.2,15,63
Prognosis
Orbital RMS has a good prognosis because of the favor-
able anatomic location, (symptoms apparent at an early stage
allowing early diagnosis), favorable histology and biology
(80% embryonal) and possibly patient age.2,37 Embryonal
RMS has a 94% 5-year survival (versus alveolar 74%) (2). Over-
all survival is excellent for groups I, II and III (92% at 5 years
and 87% at 10 years).1,14,25 Survival after relapse is depen-
dent on age at initial presentation, histology, IRS clinical
group, nodal-stage, and previous chemotherapy and
radiotherapy.65,66
Clinical cases
We present two cases that were treated at our institute
following the above-mentioned AMORE protocol.
Case 1
A 1 year old male boy was referred to our center with
proptosis OS. MR revealed a large intraorbital mass with local
Figure 4. A silicon mold with three parallel plastic tubes positioned in the
medial part of the orbit.
Figure 6. Galea flap attached to a calvarian bone, brought together to
the orbit to reconstruct the medial wall and orbital floor.
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sion (Fig. 3). A biopsy of the tumor revealed an alveolar
RMS on histology (positive for PAX3/FKHFR). There were
no metastases. The patient was treated with six courses of
IVA chemotherapy (ifosfamide, vincristine, dactinomycin) to
which the tumor responded very well, but there was some
residual tumor. External beam radiotherapy in such a young
child would lead to severe late effects and therefore the de-
layed local treatment of choice was surgery followed by
brachytherapy (AMORE protocol). The residual tumor was
macroscopically removed and in the same session a silicon
mold with three parallel plastic tubes was constructed and
positioned in the medial part of the orbit. The wound was
closed between the plastic tubes. A dose of 40 Gy in 23
pulses of 1,25 Gy was applied to treat the residual tumor area
with a high active 192Iridium source during a three-day per-
iod (Fig. 4).
The mold was removed directly afterward and the skin
closed. Following the total procedure there was good move-
ment of the eye and no strabismus. The patient is now in per-Figure 5. Galea flap attached to a calvarian bone.sistent complete remission 7 years post treatment and
without any side effects related to brachytherapy.Case 2
A 12 year old female patient presented to our clinic with a
rapidly growing mass in the left orbital/forehead area. MRI
revealed a solid soft tissue tumor, from the left ethmoidal
sinus with expansion into the maxillary sinus and the left orbit
with dural enhancement in the anterior fossa along a bone
defect. No metastasis was found on further work-up. Biopsy
revealed an embryonal RMS. The patient was started on
IVA chemotherapy (five cycles). Due to the existence of a
residual tumor it was decided to perform a macroscopic rad-
ical resection (Fig. 4) followed by brachytherapy and recon-
struction. The treatment consisted of 36 pulses of 1.25 Gy
per pulse (total dose 45 Gy), after which the patient received
four additional cycles of IVA chemotherapy. Reconstructive
surgery was performed consisting of Galea flap attached to
a calvarian bone, which were brought to the orbit to recon-
struct the medial wall and orbital floor (Figs. 5 and 6). Com-
plications secondary to brachytherapy included nasolacrimal
duct obstruction which was subsequently treated successfully
with endoscopic dacryocystorhinostomy, after which the pa-
tient complained of dry eyes. The patient is still in persistent
complete remission nine years after completion of treatment.Conclusion
Orbital RMS is one of the few life-threatening diseases
that presents first to the ophthalmologist; therefore prompt
diagnosis and treatment is a life-saving issue. Hence, knowl-
edge of the clinical, histopathological, and radiographic fea-
tures as well as the more recent advances in the management
of this entity is necessary. A multidisciplinary approach for
the treatment of orbital RMS is essential.Conflict of interest
The authors declared that there is no conflict of interest.
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